Lupus Nephritis (LN)
Immunology
2
Pipeline Programs
2
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
Vera TherapeuticsAtacicept
RegeneronVonsetamig
RegeneronVonsetamig
Clinical Trials (3)
Total enrollment: 146 patients across 3 trials
Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
Start: Nov 2022Est. completion: Dec 20280
Phase 3Withdrawn
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
Start: Aug 2022Est. completion: Sep 202756 patients
Phase 1/2Recruiting
Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis
Start: Dec 2025Est. completion: Jul 202890 patients
Phase 1Recruiting
Related Jobs in Immunology
Regulatory Affairs Manager(Immunology), Korea
AbbVie
Seoul, Seoul
12h ago
Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)
AbbVie
Remote
12h ago
Field Reimbursement Manager - Rheumatology - Seattle, WA (North)
Johnson & Johnson
Seattle, Washington, United States of America
Yesterday
$100K - $175K/yr
Senior Medical Science Liaison, Dermatology - Indianapolis
Johnson & Johnson
Indianapolis, Indiana, United States
Yesterday
$137K - $236K/yr
Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine
Johnson & Johnson
Detroit, Michigan, United States
Yesterday
Supply Chain and Procurement Controller
Ferring Pharmaceuticals
Hvidovre, Denmark
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 146 patients
2 companies competing in this space